While there is a race between countries to supply coronavirus vaccines, pharmaceutical companies are also in the race to find the vaccine suitable for children. According to the latest data, it is possible to say that Pfizer/BionTech’s work is slightly ahead of other companies. Pfizer/BionTech’s vaccine for children between the ages of 12 and 15 is ready for use for 16- to 17-year-olds while awaiting emergency approval.
As the race for access to the coronavirus vaccine continues around the world, the race to develop a vaccine suitable for children continues among the leading pharmaceutical companies developing vaccines.
Pfizer/BionTech, Oxford/AstraZeneca, Moderna, and Johnson& Johnson is working to develop the vaccine, which can be administered from 6-month-old babies until the age of 17.
However, the vaccine developed by Oxford/AstraZeneca has been put on hold due to allegations of blood clotting.
Pfizer/BionTech’s vaccine studies for children between the ages of 6 months and 2 years are still in Phase 1. Moderna and Oxford/AstraZeneca’s vaccine studies for ages 6 months-2 years are phase 2/3.
Johnson & Johnson’s vaccine is still in the clinical stage.
The vaccine studies of pharmaceutical companies between the ages of 2 and 5 are at this stage;
Pfizer/BionTech Phase 1, Moderna and Oxford/AstraZeneca Phase 2/3, and Johnson&johnson are still in clinical stages.
In vaccine studies developed for children between the ages of 5 and 11, the situation is the same as in 2-5-year-old studies. Pfizer/BionTech Phase 1, Moderna and Oxford/AstraZeneca’s Phase 2/3, Johnson & Johnson is still in the clinical stage.
Pfizer/BionTech’s vaccine for children between the ages of 12 and 15 showed 100 percent effectiveness during phase 3. Pfizer/BionTech has applied to the FDA (U.S. Food and Drug Administration) and the EMA (European Medicines Agency) for emergency use approval.
On the other hand, Moderna for children between the ages of 12 and 15 is a phase 2/3 of Oxford/AstraZeneca, while Johnson&johnson is still in the clinical stage.
Pfizer/BionTech’s vaccine for 16- to 17-year-olds is ready for use.
Finally, Moderna, Oxford/AstraZeneca, and Johnson & Johnson are in Phase 2/3.